FITC标记的磷酸化血管内皮生长因子受体2抗体上海沪震实业有限公司

金牌供应商

性能参数

产品名称: FITC标记的磷酸化血管内皮生长因子受体2抗体
英文名称: Anti-phospho-VEGF receptor 2 (Tyr1059)/FITC
抗体货号: HZ-3467R-FITC
产品规格: 100ul
级    别: 分析纯, , 分析纯,
产品产地: 中国/上海
品牌商标: HZbscience
价    格: 2980元
抗原: Rabbit
抗原来源: Rabbit
抗体来源: Rabbit
适用物种: 
FITCconjugate:FITC
应用范围: 
更新时间: 2018/8/10 13:34:00
详细资料:  实验方法技术资料
浏览人数:11
诚信指数:1084点
了解更多:进入公司展台
使用范围:仅限科研使用,不能应用于临床
点此求购
在线QQ: 我是2043711056,请问我有什么可以帮到您呢?
生物在线声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责。生物在线对此不承担任何保证责任。

供应商联系卡

上海沪震实业有限公司
地址:
上海市杨浦区密云路1018号复旦科技园808室
邮编:
200612
电话:
021-60345367
传真:
021-31320307
联系人:
陈先生
所在区域:
上海·中国-上海
邮件:
公司展台:
在线QQ:
我是2043711056,请问我有什么可以帮到您呢?
扫一扫,关注我们

产品详细描述

 Rabbit Anti-phospho-VEGF receptor 2 (Tyr1059)/FITC Conjugated antibody

FITC标记的***酸化血管内皮生长因子受体2抗体

 

英文名称 Anti-phospho-VEGF receptor 2 (Tyr1059)/FITC
中文名称 FITC标记的***酸化血管内皮生长因子受体2抗体
别    名 VEGFR2(Phospho-Tyr1059); VEGFR2(Phospho-Y1059); p-VEGFR2(Tyr1059); p-VEGFR2(Y1059); CD309; CD309 antigen; Fetal liver kinase 1; FLK-1; FLK1; KDR; Kinase insert domain receptor (a type III receptor tyrosine kinase); Kinase insert domain receptor; KRD1; Ly73; Protein tyrosine kinase receptor FLK1; Protein-tyrosine kinase receptor flk-1; Tyrosine kinase growth factor receptor; Vascular endothelial growth factor receptor 2; VEGFR 2; VEGFR; VEGFR-2; VEGFR2; VGFR2_HUMAN.  
规格价格 100ul/2980元 购买        大包装/询价
说 明 书 100ul  
产品类型 ***酸化抗体 
研究领域 肿瘤  心血管  细胞生物  免疫学  信号转导  生长因子和***  转录调节因子  血管内皮细胞  
抗体来源 Rabbit
克隆类型 Polyclonal
交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse, Rabbit, 
产品应用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 147kDa
性    状 Lyophilized or Liquid
浓    度 1mg/ml
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human VEGF receptor 2 around the phosphorylation site of Tyr1059
亚    型 IgG
纯化方法 affinity purified by Protein A
储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
产品介绍 background:
Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009].

Function:
Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA-and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Subunit:
Interacts with MYOF (By similarity). Interacts with VEGFA, VEGFC and VEGFD. Monomer in the absence of bound VEGFA, VEGFC or VEGFD. Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD. Can also form heterodimers with FLT1 and FLT4. Interacts (tyrosine phosphorylated) with FYN, NCK1, PLCG1 and SHB. Interacts with HIV-1 Tat. Interacts with CBL. Interacts with SH2D2A/TSAD and GRB2.

Subcellular Location:
Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus. 
Isoform 2: Secreted (Probable).
Isoform 3: Secreted.

Tissue Specificity:
Detected in cornea (at protein level). Widely expressed.

Post-translational modifications:
N-glycosylated. 
Ubiquitinated. Tyrosine phosphorylation of the receptor promotes its poly-ubiquitination, leading to its degradation via the proteasome or lysosomal proteases. 
Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-951 is important for interaction with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for interaction with NCK1 and FYN. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.

DISEASE:
Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma. 
Note=Plays a major role in tumor angiogenesis. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Similarity:
Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. 
Contains 7 Ig-like C2-type (immunoglobulin-like) domains. 
Contains 1 protein kinase domain.

Database links:

Entrez Gene: 407170 Cow

Entrez Gene: 482154 Dog

Entrez Gene: 3791 Human

Entrez Gene: 16542 Mouse

Entrez Gene: 25589 Rat

Omim: 191306 Human

SwissProt: P35968 Human

SwissProt: P35918 Mouse

SwissProt: O08775 Rat

Unigene: 479756 Human

Unigene: 285 Mouse

Unigene: 88869 Rat



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications
   

血管内皮生长因子(VEGF)是内皮细胞的主要生长因子。该基因编码VEGF的两个受体之一。这种受体,称为激酶插入域受体,是一种III型受体酪氨酸激酶。它作为血管内皮生长因子诱导的内皮细胞增殖、存活、迁移、管状形态发生和萌发的主要介质。该受体的信号传导和贩运受多种因素的调控,包括Rab GTPase、pY-嘌呤核苷酸受体、整合素α-β3、T细胞蛋白酪氨酸***酸酶等。该基因突变与婴儿毛细血管瘤有关。[ RefSeq,2009年5月提供]。

生物在线声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责。生物在线对此不承担任何保证责任。

查看FITC标记的磷酸化血管内皮生长因子受体2抗体产品的用户还对以下产品感兴趣

暂无

ADVERTISEMENT

找不到您所需的产品,发布求购试试?

标题:*
描述:
姓名:*
Email:*
单位:*
电话:*
地址:*
邮编:
资料: 需要 不需要
报价: 需要 不需要